Second Affiliated Hospital, School of Medicine, Zhejiang University: Lymphoma, Large B-Cell, Diffuse trials

The registry lists 11 Lymphoma, Large B-Cell, Diffuse studies with Second Affiliated Hospital, School of Medicine, Zhejiang University as lead sponsor. 6 are open to participants now and 1 have results posted.

Phase 1 3Phase 2 3No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaNot yet recruitingNCT07669194
• Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell LymphomaRecruitingNCT07078500Phase 2
• Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System LymphomaEnrolling by invitationNCT06827782Phase 1
• A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT06554600Phase 2
• Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell LymphomaRecruitingNCT06464861Phase 1
• Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPIRecruitingNCT06290817Phase 2
• 18F-FDG PET Radiomics of Diffuse Large B-cell LymphomaCompletedNCT04317313Results posted
• Combining Intratumoral Metabolic Heterogeneity and Dissemination Feature (Dmax) on 18F-FDG PET/CT Improves Prognosis Prediction in DLBCLCompletedNCT05113576
• the Effect of Broken Ganoderma Lucidum Spore Powder on Quality of Life and Immune Function in Patients With Diffuse Large B-cell Lymphoma After ChemotherapyStatus unknownNCT04914143Not applicable
• Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell LymphomaCompletedNCT04833504
• CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell LymphomaStatus unknownNCT04381741Phase 1